Bladder Cancer

IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti Tumor Activity
ImmunityBio Expects To Submit US Application For VesAnktiva In Bladder Cancer This Month
ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting
ImmunityBio Expects To Submit US Application For VesAnktiva In Bladder Cancer This Month
ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
IMV's Basket Clinical Study Shows Promising Top Line Data In Bladder Cancer

Bladder Cancer Recent News

ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
Janssen Shares Erdafitinib Combo Therapy Data In Bladder Cancer
FDA Extends Full Approval For Merck's Keytruda In 1st-Line Bladder Cancer
After FDA Rejection Troubled Biotech Pulls Europe Application For Bladder Cancer Drug
Two weeks ago, Sesen Bio Inc (NASDAQ: SESN) was on the cusp of winning FDA approval for the cancer drug Vicineum.
Bristol Myers Scores FDA Approval For Opdivo In Postsurgery Bladder Cancer
Sesen Bio's Bladder Cancer Trial Wrecked By Misconduct: Stat News
Sesen Bio Inc (NASDAQ: SESN) said that it was not expecting a CRL from the FDA for its bladder cancer candidate Vicineum. 
Sesen Bio Stock Crashes As FDA Shoots Down Its Bladder Cancer Pitch
Fusion Pharma Stock Is Trading Higher As FDA Clears Early-Stage Study For Radiopharmaceutical In Neck, Bladder Cancers
G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela
Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder Cancer
Roche Walks Away From Regular FDA Nod For Tecentriq In Pretreated Bladder Cancer
Roche Holding AG (OTCMKT: RHHBF) has joined AstraZeneca Plc (NASDAQ: AZN) in withdrawing cancer immunotherapies from the U.S.
Sesen Bio's Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike
For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'